# LEAC-102 for Advanced Colorectal Cancer

> **NCT02826837** · PHASE1,PHASE2 · UNKNOWN · sponsor: **Taiwan Leader Biotech Corp.** · enrollment: 30 (estimated)

## Conditions studied

- Advanced Colorectal Cancer

## Interventions

- **DRUG:** LEAC-102 500mg capsule and FOLFOX + Bevacizumab/Cetuximab

## Key facts

- **NCT ID:** NCT02826837
- **Lead sponsor:** Taiwan Leader Biotech Corp.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2022-09-01
- **Primary completion:** 2024-02-01
- **Final completion:** 2024-02-01
- **Target enrollment:** 30 (ESTIMATED)
- **Last updated:** 2021-10-06


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02826837

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02826837, "LEAC-102 for Advanced Colorectal Cancer". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT02826837. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*